Mendus AB Sustainability Reports
Mendus AB is a clinical-stage biopharmaceutical company leveraging allogeneic dendritic cell biology to develop cell-based immunotherapies. It focuses on changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival.
Sector: Manufacturing
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 529900AFBGFR7ZB50J95
FIGI: BBG004G0BR56
10 reports from 2016 to 2025
